How Doctors Adjust Cosentyx Dosing Based on Patient Response
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions, starts with a loading dose followed by maintenance. For plaque psoriasis, adults typically get 300 mg weekly for the first 4-5 weeks (subcutaneous injection), then 300 mg every 4 weeks. For psoriatic arthritis or ankylosing spondylitis, it's 150-300 mg every 4 weeks after initial doses.[1]
If patients achieve clear or almost clear skin (PASI 90-100 response) or significant symptom relief by week 12-16, doctors often reduce frequency to every 8 weeks to maintain efficacy while minimizing injections and potential side effects like infections.[1][2]
What Happens If Response Is Inadequate
Non-responders or partial responders (e.g., less than PASI 75 improvement) by week 12-16 may continue every 4 weeks, get dose escalated to 300 mg if on 150 mg, or switch therapies. Clinical trials like FUTURE 5 showed 77% of psoriatic arthritis patients on 150 mg every 4 weeks reached ACR20 response at week 16, but non-responders rarely improved further without changes.[2][3]
Retreatment applies if relapse occurs: patients restart loading doses then resume maintenance.[1]
Factors Beyond Response Influencing Frequency Changes
- Disease Severity and Type: Higher doses/more frequent for psoriasis (300 mg) vs. arthritis (150 mg if adequate).[1]
- Body Weight: Some evidence supports 300 mg for patients over 90 kg to boost response rates.[3]
- Guidelines: American Academy of Dermatology recommends spacing to every 8 weeks for good responders to reduce burden; European guidelines align for psoriasis.[4]
- Patient Concerns: Fewer injections cut infection risk (e.g., upper respiratory, 10-15% incidence) and injection-site reactions (10-20%).[1][2]
When Patents and Biosimilars Might Affect Access to Adjusted Dosing
Cosentyx patents expire in the US around 2032-2033 for key method-of-use claims, per DrugPatentWatch; challenges from Amgen and others are ongoing, potentially allowing biosimilars earlier and enabling cheaper dose optimization.[5]
[1]: Cosentyx Prescribing Information, Novartis, 2023. https://www.cosentyx.com/
[2]: Mease PJ et al., Lancet 2018 (FUTURE 5 trial). https://pubmed.ncbi.nlm.nih.gov/29336848/
[3]: Armstrong AW et al., J Am Acad Dermatol 2021. https://pubmed.ncbi.nlm.nih.gov/33549591/
[4]: Menter A et al., J Am Acad Dermatol 2019 (AAD guidelines). https://www.jaad.org/article/S0190-9622(18)32923-3/fulltext
[5]: DrugPatentWatch.com, Secukinumab patents. https://www.drugpatentwatch.com/p/tradename/COSENTYX